Antidpressant, Fluvoxamine, Reduces Severe Covid-19 Disease, Study FindsBy Radiant Health
Published: October 31, 2021
A new study published in Lancet Global Health found that a 10-day course of fluvoxamine (brand name Luvox), a drug commonly prescribed for depression and obsessive-compulsive disorder, significantly reduced the need for hospitalization by 66% and cut deaths by 91% in people at high risk of severe covid-19 disease. A full treatment course with fluvoxamine costs about $10 compared to $700 for a 5-day treatment course with Merck’s antiviral pill, molnupiravir. The expert panel that develops US Covid-19 treatment guidelines has been briefed on the study data and could decide soon about recommending fluvoxamine as an early treatment.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- Kool-Aid And Other Sweet Drinks Recalled for Glass and Metal Pieces - November 28, 2021
- Covid-19 Cases in Children Spike Dramatically - November 28, 2021
- Omicron, A New Coronavirus Variant, Fuels Concerns Worldwide - November 28, 2021
- Major Pharmacies in Ohio to Pay for Opioid Crisis - November 28, 2021
- White Chocolate Bark with Okra, Raspberries, and Papaya - November 21, 2021
- The FDA Expands Covid-19 Vaccine Booster Dose for All Adults - November 21, 2021
- U.S. Drug Overdoses Rose Sharply Last Year - November 21, 2021
- Epidemiologists Warn of Covid-19 Winter Surge - November 21, 2021
- Pfizer’s Antiviral Pill Will Be Sold to Dozens of Poor Nations at a Discount - November 21, 2021
- Breathwork: How To Reduce Stress With Breathing Exercises - November 13, 2021